GTF3C2

Across TCGA pan-cancer cohorts, GTF3C2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GTF3C2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GTF3C2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GTF3C2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where GTF3C2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.532	0.854	.003	32	view →
LSCC	DFS	Quartile	II,III,IV	0.939	0.489	.008	17	view →
CCRCC	OS	Median	II,III,IV	0.867	1.000	.032	10	view →
GBM	OS	Tertile	All	0.554	0.280	.009	5	view →
HNSC	OS	Tertile	All	0.795	0.899	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GTF3C2–PDAC (DFS)

Open the PDAC breakdown →